68Ga-labeled NY104 PET Imaging in Patients
NCT05638256 · Status: UNKNOWN · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 10
Last updated 2022-12-06
Summary
This is a single arm study to evaluate the safety and biodistribution of 68Ga-labeled NY104 PET Imaging in patients with Renal Cell Carcinoma
Conditions
Interventions
- DRUG
-
68Ga-NY104
Patients will receive a tracer (20-40mcg, IV) dose of 68Ga (2-5mCi) labelled NY104
Sponsors & Collaborators
-
Affiliated Hospital of Jiangnan University
lead OTHER
Study Design
- Allocation
- NA
- Purpose
- DIAGNOSTIC
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2022-10-10
- Primary Completion
- 2023-10-31
- Completion
- 2023-10-31
Countries
- China
Study Locations
More Related Trials
-
68Ga-NY104 PET/CT in Patients With Metastatic Clear Cell Renal Cell Carcinoma
NCT05879471 ·Status: UNKNOWN ·Phase: PHASE2
-
68Ga-PSMA PET in the Renal Cell Carcinoma
NCT04987086 ·Status: RECRUITING ·Phase: NA
-
68Ga-NYM096 PET/CT in Various Kinds of Cancer
NCT07144748 ·Status: RECRUITING ·Phase: NA
-
A Small-molecule Carbonic Anhydrase IX Targeting PET Tracer in Clear Cell Renal Cell Carcinoma
NCT05728515 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
68Ga-N188 PET/CT Imaging in Malignancy
NCT05593107 ·Status: RECRUITING ·Phase: NA
-
Exploring the Clinical Application Value of CAIX-Targeted PET Imaging in Renal Cancer Patients
NCT06956144 ·Status: RECRUITING
-
68Ga-NY104 PET/CT for the Detection of Clear Cell Renal Cell Carcinoma in Presurgical Patients With Renal Masses
NCT05879510 ·Status: UNKNOWN ·Phase: PHASE2
-
Clinical Application of 18F-labeled RD2 PET/CT Imaging in the Diagnosis and Treatment of Small Liver Carcinoma
NCT05681234 ·Status: COMPLETED ·Phase: NA
-
Multicenter Study of 18F-Labeled NY104 for PET/CT Imaging in Renal Cell Carcinoma
NCT06916624 ·Status: RECRUITING
-
CD70-targeted immunoPET Imaging of Kidney Cancer
NCT06680089 ·Status: RECRUITING ·Phase: PHASE2
-
68Ga-NYM096 PET/ CT for the Detection of Clear Cell Renal Cell Carcinoma in Presurgical Patients With Renal Masses
NCT07101900 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE2
-
Clinical Application of PET Imaging Targeting GPA33 in Malignant Tumors
NCT07172503 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
68Ga-C1 PET/ CT Imaging in Clear Cell Renal Cell Carcinoma
NCT06519760 ·Status: RECRUITING ·Phase: NA
-
89Zr-labeled NY008 PET Imaging in Patients
NCT05655676 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
68Ga-BNU-PSMA PET/CT in Patients With Various Types of Cancer
NCT04525612 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
Clinical Evaluation of [68Ga]Ga-XT771 PET for Diagnosis in Patients With Glioblastoma and Clear Cell Renal Cell Carcinoma
NCT07067905 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
68Ga-BNOTA-PRGD2 PET/CT in Healthy Volunteers and Lung Cancer Patients
NCT01527058 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
CD70-targeted immunoPET Imaging of Malignant Cancers
NCT06852638 ·Status: RECRUITING ·Phase: PHASE2
-
Diagnosis of Renal Cell Carcinoma on 68Ga-PSMA PET-CT and Radioligand Therapy With 177Lu-EB-PSMA-617
NCT05170555 ·Status: UNKNOWN ·Phase: NA
-
PET Image Exploration of Novel Tracer [68Ga]-FAPI-JNU Imaging Studies in Patients with Malignant Tumors
NCT06684028 ·Status: RECRUITING ·Phase: NA
-
68Ga-DOTA-F2 PET/CT in Patients With Various Types of Cancer
NCT05637034 ·Status: UNKNOWN ·Phase: NA
-
Clinical Application of PET Imaging Targeting Nectin-4 in Malignant Tumors
NCT06994078 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
68Ga-P16-093 and 18F-FDG PET/CT Imaging in the Same Group of Clear Cell Renal Cell Carcinoma Patients
NCT05432947 ·Status: COMPLETED ·Phase: NA
-
68Ga-NOTA-NFB: Radiation Dosimetry in Healthy Volunteers and Applications in Glioma Patients or Breast Cancer Patients
NCT02327442 ·Status: UNKNOWN
-
68Ga-JH12 PET/CT: Dosimetry and Biodistribution Study
NCT06688188 ·Status: RECRUITING ·Phase: EARLY_PHASE1